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Summary A patient with the midgut carcinoid syndrome with severe diarrhoea and proven hypersecretion of
serotonin (5-HT) was treated with low doses of verapamil perorally. During treatment the patient was
completely relieved of diarrhoea but discrete facial flushing persisted during treatment. When treatment was
cessated, diarrhoeas recurred. This patient underwent pentagastrin (PG) provocation repeatedly; during
untreated conditions injection of PG released 5-HT, detectable in peripheral venous blood. Such release was
abolished during verapamil treatment, but recurred after withdrawal of the drug. Surgical biopsies from this
tumour were studied in two experimental models: cell suspensions and heterotransplants grown in the anterior
eye-chamber of immunosuppressed rats. Release of 5-HT from the cell suspensions was elicited in a dose-
dependent manner after stimulation with isoprenaline (IP) suggesting activation of ,B-adrenoceptors on the
tumour cells. Such release was reduced after pretreatment with verapamil indicating a calcium dependent
mechanism. Intraocular tumour transplants also responded with release of 5-HT into the chamber fluid after
conjunctival application of IP. However, pretreatment of the rats with verapamil significantly reduced the IP-
stimulated release of 5-HT.
Human carcinoid tumours of midgut origin
produce and secrete large amounts of serotonin (5-
HT). This monoamine has an established patho-
genetic role in the development of diarrhoea and
may also be involved in other symptoms of the
carcinoid syndrome (cf. Grahame-Smith, 1972).
5-HT antagonists, i.e. methysergide or cypro-
heptadine, have been used with variable success in
the treatment of carcinoid diarrhoea (cf. Ahlman,
1985). Selective antagonists of 5-HT2 receptors, i.e.
ketanserin, offered theoretically a more attractive
therapeutic approach with less side effects.
Although ketanserin was of therapeutic value in
many patients with the carcinoid syndrome
(Gustafsen et al., 1985), a few patients had no
symptomatic relief at all (Ahlman et al., 1985).
Such failure could be ascribed to secretion of
compounds other than 5-HT by the tumour, e.g.
bradykinin or substance P (Oates et al., 1964,
Strodel et al., 1984).
In order to study the release of 5-HT from
carcinoid tumour cells we have recently developed
an experimental model with heterotransplantation
of human carcinoid tumours into the anterior eye-
chamber of immunosuppressed rats (Nilsson et al.,
1985a). The physiological release of 5-HT from gut
enterochromaffin (EC) cells is controlled by f,-
adrenoceptors (Ahlman & Dahlstr6m, 1983) and
also carcinoid heterotransplants have an adreno-
ceptor controlled release mechanism (Nilsson et al.,
1985a,b). In vitro studies on tumour cell
suspensions demonstrated that the release was
blocked not only with P-adrenoceptor antagonists,
but also with verapamil, a calcium channel blocker
(Nilsson et al., 1985b). This drug has previously
been reported to block the release of several
hormones under experimental conditions, e.g. from
the anterior pituitary gland (Matsumura et al.,
1984; Veldhuis et al., 1985), the endocrine pancreas
(Ohneda et al., 1983) and antral G-cells (Fiddian-
Green et al., 1983; Harty et al., 1984).
The purpose of the present study was to evaluate
the clinical effect of verapamil in the midgut
carcinoid syndrome and the effect on provoked 5-
HT release. Therefore we compared the release of
5-HT from cell suspensions and in oculo hetero-
transplants from the same tumour after adreno-
ceptor stimulation, and the influence of verapamil
pretreatment in both systems was evaluated.
Provocation of 5-HT release by pentagastrin (PG)
was studied clinically in this patient before and
during treatment with verapamil as well as after
withdrawal of the drug.
Materials and methods
Clinical history
This patient (male, age 74) suffered from severe
bouts of diarrhoea (daily frequency 10-15) and
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daily flushing since 3 months. Both facial flush and
diarrhoea occurred regularly after the morning
meal. From the preoperative investigation (CTscan,
angiography) the patient was demonstrated to have
an ileal tumour with large mesenteric lympho-
glandular metastases and biliary spread to the liver.
Urinary levels of 5-hydroxyindoleacetic acid were
clearly elevated (12-18mmolmol-1 creatinine; ref.
value 1-6). The patient had tried medical therapy
(codeine, loperamide, diphenoxylate or ketanserin)
for diarrhoea with little symptomatic relief. At
surgery an ileal resection was performed as well as
a debulking procedure directed against the large
lymphogranular metastases in the mesenteric root.
Tumour material
The tumour had argyrophil and argentaffin staining
properties and demonstrated a large proportion
(>90%) of 5-HT immunoreactive cells. Fresh
tumour material was obtained from the primary
tumour, which was placed in ice-cooled, oxygenated
Krebs' solution for 15-30min prior to
transplantation or preparation of tumour cell
suspensions.
Clinicalprovocation with PG
Prior to surgery peripheral venous blood samples
were drawn from the patient (fasting overnight)
twice before (basal levels) and 1, 3 and 5min after
injection of PG (0.6 ugkg1 i.v.). Provocation with
PG was performed (a) at admission to hospital (no
medication), (b) after chronic peroral treatment
with verapamil, (c) 1 week after cessation of
verapamil. Since this drug is a widely used anti-
hypertensive agent with few adverse effects, a
clinical trial in patients with the carcinoid syndrome
was recently approved by the Ethical Committee of
the University of Goteborg.
Samples of whole blood (1 ml) were added to
heparinized glass tubes containing 4ml of distilled
water (0.01% ascorbic acid added) and stored on
ice. After complete haemolysis precipitation with
0.5ml IM NaOH and Iml 10% ZnSO4 was
performed. The samples were centrifuged at 200g
for 20min and the sediments were discarded. In
parallel samples, known amounts of 5-HT
creatinine sulphate (25-lOOpmol) were added to
correct for recovery. Analyses were performed using
Liquid Chromatography with Electro Chemical
detection (LCEC) (cf. Ponzio & Jonsson, 1978).
The supernatants were added to the columns in
10p1 aliquots without further processing. Recovery
of authentic 5-HT added averaged 72+5%.
Standard curves were made by injecting standard
solutions (2.5-10pmol in 10p1), prepared by
dissolving 5-HT creatinine sulphate in 0.1 M
perchloric acid.
Tumour cell suspensions
Fresh tumour material was thoroughly cleared of
surrounding tissue, cut into small pieces and put
into a 2% collagenase solution. Three hundred !d
of a 0.04% DNAse solution/lOml collagenase
solution was added to obtain a monodispersed cell
suspension with maximal viability. The suspension
was stirred for 60min at room temperature under
continuous oxygenation and thereafter filtered
through a double layer of sterile gauze. The
suspension was then centrifuged at 175g for 5min
and washed and resuspended twice in Kreb's
solution to remove the collagenase solution. The
technique for preparation of tumour cell
suspensions has been previously described in detail
by Skolnik (1982). The cell viability in the final
suspension was estimated after nigrosin staining
according to Kaltenbach et al. (1958) and was 87%.
The suspensions were diluted to a final
concentration of 1 x 106 viable tumour cells ml-1.
The cell suspensions were incubated at 37°C
in oxygenated Kreb's solution alone (=control)
or with noradrenaline (NA) (10-6-10-4 M),
adrenaline (A) (10-6-10-4M) or isoprenaline (IP)
(10-6-10-4 M) added to the incubation medium. In
all vials ascorbic acid (final concentration 0.01%)
was added to the incubation medium to protect
5-HT and the adrenoceptor agonists from
degradation. After 1-15min of incubation, small
samples (70p1) were withdrawn and centrifuged at
10,OOOg for 30-60sec in an Airfuge (Beckman Inst.
Inc.). The clear supernatant was decanted and
immediately frozen at -20°C until 5-HT assay.
Animals
Male Sprague-Dawley rats (ALAB, Sollentuna,
Sweden), weighing 100-150g, were used as recipient
animals for the transplantation experiments.
Cyclosporin A (Sandoz AG, Basel, Switzerland)
was injected s.c. (20mgkg-1 day-1) starting the day
before transplantation. Animals were allowed free
access to food and water and were kept in rooms
with a 12h dark/light cycle.
In oculo transplantation
Small tumour tissue pieces (1 mm3) were dissected
and manipulated to the lateral margin of each eye
chamber by a technique previously described in
detail (Nilsson et al., 1985a). The transplants were
rapidly vascularized (within 2-3 days) and retained
the immunocytochemical profile of the original
human tumour (Nilsson et al., 1985a,b). After 7-10
days in oculo the transplants were pharma-
cologically stimulated via conjunctival application
of solutions containing 0.1%NA, 0.1%A, 0.1% IP
or 0.9%NaCl under light ether anaesthesia. AfterVERAPAMIL AND CARCINOID DIARRHOEA 253
15min a small incision was made in the cornea and
chamber fluid (5-10jl) was withdrawn and assayed
for 5-HT.
The experiments were repeated in the same rats
after pretreatment with verapamil in two different
doses (0.5mgkg-1 or 1.Omgkg-1i.v.) 15min prior
to application of IP.
Results
Clinicalprovocation with PG
At the initial PG test, basal 5-HT levels were not
elevated, but within 1min after PG injection the
patient developed facial flushing and complained
about abdominal cramps. Simultaneously peripheral
5-HT levels in whole blood were increased. The
clinical and biochemical response declined after
5min (Figure 1). The patient was thereafter treated
with verapamil (IsoptinR 40mg x 3p.o.). After 2
weeks the patient complained about constipation
and the dose was reduced to 40mg x 2. After a
total treatment period of 10 weeks PG provocation
was again performed. The basal levels of 5-HT
were now low and no peak was demonstrated after
PG injection (Figure 1). The patient developed a
mild facial flush but no gastrointestinal symptoms.
To prove that the observed improvement was due
to the drug therapy, verapamil treatment was
suspended for 1 week. At the end of this period the
patient had a few daily bouts of diarrhoea and PG
provocation induced a similar clinical and bio-
chemical response as in the untreated condition
(Figure 1).
Tumour cell suspensions
The results of the stimulation experiments
performed on carcinoid tumour cells in suspension
are shown in Table I. The tumour cells released
5-HT into the incubation medium upon stimulation
with IP (10-5-10-4M) in a dose-dependent
manner but not after stimulation with A or NA.
Pretreatment with verapamil (10-6 M) caused a
pronounced reduction of the IP-induced (10- M)
5-HT release (Figure 2). The release in this
experimental group still exceeded the unstimulated
tumour cell suspension studied during the same
time interval (Figure 2).
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Figure 2 The release of 5-HT at stimulation of 1-
adrenoceptors (IP 10-5 M) in a tumour cell suspension
(t.c.s.) was inhibited after pretreatment with verapamil
(10-6 M).
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Figure 1 Levels of 5-HT in peripheral venous whole
blood at provocation with PG (0.6ygkg-1i.v.) in a
patient with the midgut carcinoid syndrome. The PG
test was performed initially under untreated conditions
(0). The PG-test was repeated after chronic treatment
with verapamil perorally (0). After cessation of the
drug for one week a third PG test was performed (A).
In oculo experiments
The results of the stimulation experiments
performed in heterotransplants in oculo are
summarized in Figure 3. Transplants in 8 animals
released 5-HT into the chamber fluid upon
application of IP in great excess of the 5-HT
concentration observed in eyes with local saline
application alone. The release was significantly
reduced (P<0.01) after systemic pretreatment of the
recipient animals with verapamil (0.5mgkg- i.v.).
No further reduction was achieved by a higher dose
of verapamil (l.Omgkg 1 i.v.).
Discussion
The exact mechanism underlying the 5-HT response
to PG has not been clarified. In vitro studies of
carcinoid tumour cell suspensions after incubation
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Table I The effects of adrenoceptor agonists on 5-HT release from a suspension
ofcarcinoid tumour cells (t.c.s. =tumour cell susp.)
Agonist 2min 7-10min 15min
t.c.s. 3.9+ 1.0 5.2+0.8 5.9+ 1.1 ng5-HTml -
(n=6)
t.c.s.+NA 10-6M 7.3 6.7 11.8 ng5-HTml-
t.c.s.+NA 10-5M 16.8 11.2 12.3 ng5-HTml-1
t.c.s.+NA 10-4M 6.2 5.0 7.2 ng5-HTml -
t.c.s.+A 10-6M 8.7 9.0 0.9 ng5-HTml-
t.c.s.+A 10-5M 5.6 6.2 4.5 ng5-HTml -
t.c.s.+A 10-4M 4.5 6.2 6.2 ngS-HTml-'
t.c.s.+IP 10-6M
t.c.s.+IP 10-5M
t.c.s.+IP 10-4M
11.2
256.2
1596
13.4
319.2
1540
8.4
159.6
1218
ngS-HTml-
ngS-HTml -1
ngS-HTml -
with PG have not documented any 5-HT release
(Nilsson et al., 1985a). This fact may indicate that
PG has an indirect mode of action, unless
preparation of cell suspensions destroys specific
gastrin receptors on the tumour cell surface. During
the clinical PG test a moderate fall in systemic
arterial blood pressure was noted in most patients
(Ahlman et al., 1985). Therefore, an indirect
mechanism, operating via compensatory release of
catecholamines from the adrenals or sympathetic
nerves, is possible and has experimental support
(Gronstad et al., 1985).
In the present patient the PG-induced release of
5-HT was prevented after chronic treatment with
verapamil. The disabling diarrhoea disappeared
completely, while slight facial flushing persisted.
This finding is compatible with 5-HT as mediator
of gastrointestinal symptoms but not of cutaneous
vasomotor symptoms (cf. Ahlman, 1985). The
thereapeutic effect observed was most probably due
to verapamil, since withdrawal of the drug was
followed by recurrence of gastrointestinal symptoms
and restitution of the original biochemical response
to PG provocation (Figure 1).
In the two experimental models the release of
5-HT at adrenoceptor stimulation was studied. We
have previously demonstrated a common pattern of
responsiveness to adrenoceptor stimulation between
the two models; with most tumours responsive to
f3-adrenoceptor stimulation (Nilsson et al., 1985ab).
This was also the case in these experiments with a
dose-dependent response to stimulation with IP in
cell suspensions (Table I) and a prominent response
to IP in the heterotransplants (Figure 3). The
response to IP (10-5 M) in vitro was markedly
reduced after pretreatment with verapamil in an
.5-
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Figure 3 The release of 5-HT from heterotransplants
of the carcinoid tumour in oculo in immunosuppressed
rats. Conjunctival application of 0.1% IP caused a
pronounced release of 5-HT into each eye-chamber
compared with controls (application of 0.9%NaCI). If
the same animals were pretreated with verapamil
(0.5mgkg-I or lmgkg-li.v.) the IP-induced release
of 5-HT was significantly reduced (*P<0.01;
n =number ofeye-chambers studied).VERAPAMIL AND CARCINOID DIARRHOEA 255
even lower concentration (10-6 M) (Figure 2). A
significant reduction of the IP-induced release of
5-HT into the anterior eye-chamber was also
demonstrated after pretreatment with verapamil.
The reduction of the response was not further
influenced by using a higher dose of the drug
(Figure 3). To summarize, the release of 5-HT at
clinical provocation with PG, which may operate
via activation of adrenoceptors (cf. Gronstad et al.,
1985), was reduced by verapamil in accordance
with the reduction seen at stimulation of f-
adrenoceptors in both experimental models.
Verapamil was recently tested in another patient
with severe therapy-resistant diarrhoea due to 5-HT
secretion from a midgut carcinoid tumour. In the
PG test the basal 5-HT-levels increased from
90-104ngml-1 to 2IOngml-P within 3min
accompanied by facial flushing and abdominal
cramps. The test was repeated the following day
after verapamil (5nmgi.v. 10min prior to provoca-
tion). The second test still resulted in flushing,
while 5-HT levels remained stable (69-78ngml-1)
throughout the test period. This patient was also
relieved from diarrhoea within 5 days of verapamil
treatment (40mg x 3p.o.) and has remained so
during the preoperative work-up. A third patient
with a different type of severe endocrine diarrhoea
due to hypersecretion of calcitonin (medullary
thyroid carcinoma) was also tested on chronic
verapamil treatment (40mg x 3p.o.). This patient
had elevated basal levels of calcitonin with a peak
reaction at PG injection, while 5-HT levels were
within the normal range and did not react at PG
injection. There was no therapeutic effect of the
drug on diarrhoea in this patient and the release of
calcitonin at PG provocation was unchanged.
If there is a selective action of verapamil on 5-
HT induced diarrhoea, this may be due to pharma-
cological effects in addition to blockade of slow
calcium channels, e.g. antagonism of 5-HT2
receptors (cf. Affolter et al., 1985). Such dual
effects of the drug might explain why the
therapeutic dose was so low in each one of the
patients with carcinoid disease (about half of the
dose used in the treatment of hypertension), unless
this type of endocrine neoplasia has a high
sensitivity to the drug.
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